Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Autologous tumour infiltrating lymphocytes - Shanghai Juncell Therapeutics

X
Drug Profile

Autologous tumour infiltrating lymphocytes - Shanghai Juncell Therapeutics

Alternative Names: GC 101 TIL injection; TILS - Shanghai Gencells Therapeutics; Tumor infiltrating lymphocytes - Shanghai Gencells Therapeutics

Latest Information Update: 28 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Juncell Therapeutics
  • Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies; Tumour infiltrating lymphocyte therapies
  • Mechanism of Action Immunologic cytotoxicity; Lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Malignant melanoma
  • Phase I Breast cancer; Gastrointestinal stromal tumours; Solid tumours
  • No development reported Glioma

Most Recent Events

  • 28 Jun 2024 No recent reports of development identified for phase-I development in Glioma(Metastatic disease, Second-line therapy or greater) in China (IV)
  • 26 Jun 2024 Shanghai Juncell Therapeutics plans a phase I MIZAR-005 trial for Non small cell lung cancer (Metastatic disease, Late-stage disease, Inoperable/Unresectable, Second-line therapy or greater, Recurrent) (Parenteral) (NCT06473961)
  • 08 Nov 2023 Phase-I/II clinical trials in Malignant melanoma (Late-stage disease, Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable, Recurrent) in China (IV) (NCT06120712)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top